J. B. Chemicals & Pharmaceuticals Future Growth
Future criteria checks 4/6
J. B. Chemicals & Pharmaceuticals is forecast to grow earnings and revenue by 17.5% and 11.7% per annum respectively. EPS is expected to grow by 17.5% per annum. Return on equity is forecast to be 20.6% in 3 years.
Key information
17.5%
Earnings growth rate
17.5%
EPS growth rate
| Pharmaceuticals earnings growth | 17.4% |
| Revenue growth rate | 11.7% |
| Future return on equity | 20.6% |
| Analyst coverage | Good |
| Last updated | 27 May 2024 |
Recent future growth updates
Recent updates
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19
J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50
Feb 16With EPS Growth And More, J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Interesting
Jan 27J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Could Easily Take On More Debt
Nov 30Here's Why I Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Might Deserve Your Attention Today
Sep 24Are J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Investors Paying Above The Intrinsic Value?
Aug 03Do J. B. Chemicals & Pharmaceuticals's (NSE:JBCHEPHARM) Earnings Warrant Your Attention?
Jun 14How Does J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Fare As A Dividend Stock?
May 04Do J. B. Chemicals & Pharmaceuticals's (NSE:JBCHEPHARM) Earnings Warrant Your Attention?
Mar 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 51,346 | 9,715 | -1,401 | 10,860 | 4 |
| 3/31/2026 | 45,734 | 8,590 | 8,084 | 8,988 | 11 |
| 3/31/2025 | 40,524 | 7,030 | 6,375 | 7,585 | 13 |
| 3/31/2024 | 35,215 | 5,526 | 5,393 | 8,006 | N/A |
| 12/31/2023 | 33,848 | 5,141 | N/A | N/A | N/A |
| 9/30/2023 | 33,330 | 4,866 | 2,888 | 7,680 | N/A |
| 6/30/2023 | 32,607 | 4,471 | N/A | N/A | N/A |
| 3/31/2023 | 31,493 | 4,098 | -1,393 | 6,256 | N/A |
| 12/31/2022 | 30,115 | 4,071 | N/A | N/A | N/A |
| 9/30/2022 | 28,195 | 3,848 | -7,379 | 3,122 | N/A |
| 6/30/2022 | 26,031 | 3,715 | N/A | N/A | N/A |
| 3/31/2022 | 24,242 | 3,854 | -5,367 | 1,701 | N/A |
| 12/31/2021 | 23,281 | 4,011 | N/A | N/A | N/A |
| 9/30/2021 | 22,757 | 4,713 | 3,154 | 3,745 | N/A |
| 6/30/2021 | 21,262 | 4,474 | N/A | N/A | N/A |
| 3/31/2021 | 20,425 | 4,480 | 2,670 | 3,148 | N/A |
| 12/31/2020 | 19,576 | 3,975 | N/A | N/A | N/A |
| 9/30/2020 | 18,381 | 3,097 | 1,178 | 1,786 | N/A |
| 6/30/2020 | 18,509 | 3,295 | N/A | N/A | N/A |
| 3/31/2020 | 17,747 | 2,720 | 2,028 | 2,757 | N/A |
| 12/31/2019 | 17,501 | 2,686 | N/A | N/A | N/A |
| 9/30/2019 | 17,035 | 2,521 | 2,148 | 2,749 | N/A |
| 6/30/2019 | 16,824 | 2,098 | N/A | N/A | N/A |
| 3/31/2019 | 16,432 | 1,935 | 1,452 | 1,943 | N/A |
| 3/31/2018 | 14,084 | 1,383 | 865 | 1,229 | N/A |
| 3/31/2017 | 13,443 | 1,841 | N/A | 2,011 | N/A |
| 3/31/2016 | 12,104 | 1,625 | N/A | 1,404 | N/A |
| 3/31/2015 | 11,442 | 1,004 | N/A | 1,267 | N/A |
| 3/31/2014 | 10,219 | 615 | N/A | -140 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JBCHEPHARM's forecast earnings growth (17.5% per year) is above the savings rate (6.7%).
Earnings vs Market: JBCHEPHARM's earnings (17.5% per year) are forecast to grow faster than the Indian market (16% per year).
High Growth Earnings: JBCHEPHARM's earnings are forecast to grow, but not significantly.
Revenue vs Market: JBCHEPHARM's revenue (11.7% per year) is forecast to grow faster than the Indian market (9.4% per year).
High Growth Revenue: JBCHEPHARM's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JBCHEPHARM's Return on Equity is forecast to be high in 3 years time (20.6%)